Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
<p>Abstract</p> <p>Background</p> <p>The vinka-alkaloyd vinorelbine is a potentially valuable treatment in patients with HER2-positive, trastuzumab-resistant advanced breast cancer. We sought to document the clinical activity of vinorelbine-based salvage treatments in t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-07-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/8/209 |
| _version_ | 1818529997047988224 |
|---|---|
| author | Viale Giuseppe Valabrega Giorgio Jacomuzzzi Maria Donadio Michela Nolè Franco Redana Stefania Montemurro Filippo Sapino Anna Aglietta Massimo |
| author_facet | Viale Giuseppe Valabrega Giorgio Jacomuzzzi Maria Donadio Michela Nolè Franco Redana Stefania Montemurro Filippo Sapino Anna Aglietta Massimo |
| author_sort | Viale Giuseppe |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The vinka-alkaloyd vinorelbine is a potentially valuable treatment in patients with HER2-positive, trastuzumab-resistant advanced breast cancer. We sought to document the clinical activity of vinorelbine-based salvage treatments in this clinical setting.</p> <p>Methods</p> <p>We analyzed a cohort of 424 consecutive women receiving trastuzumab-based therapy for HER2-positive advanced breast cancer. Of these, 299 were identified as progressing during the initial trastuzumab-based treatment, and 77 received vinorelbine-based therapy as first salvage treatment. Central review of pathological specimens revealed that 70 patients had HER2-amplification detected by FISH. For these patients we determined overall response rate (ORR = complete-CR + partial-PR) and clinical benefit (CB = CR+PR+ Stable disease lasting at least 6 months), time to progression (TTP) and overall survival (OS) from the initiation of vinorelbine-based salvage therapy.</p> <p>Results</p> <p>In 60 patients who were evaluable for tumor response, ORR and CB rates were 28% (95% C.I. 18%-41%) and 50% (95% C.I. 38%-62%), respectively. Median follow-up from the initiation of salvage therapy was 15 months (range 1–63 months). Median TTP and OS were 7.1 months (95% C.I. 6.6–7.7 months) and 21 months (95% C.I. 14.3–27.7 months), respectively. No differences in clinical outcomes were observed according to whether vinorelbine was administered as a single agent or in combination with other cytostatics, or whether trastuzumab was stopped or continued beyond disease progression.</p> <p>Conclusion</p> <p>our findings suggests that vinorelbine-based combinations are active and should be further evaluated in studies conducted in trastuzumab-resistant patients, including those evaluating newer HER2-targeting agents.</p> |
| first_indexed | 2024-12-11T17:14:08Z |
| format | Article |
| id | doaj.art-0016198fb9fa4f8b90de6a96991c34e7 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-11T17:14:08Z |
| publishDate | 2008-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-0016198fb9fa4f8b90de6a96991c34e72022-12-22T00:57:23ZengBMCBMC Cancer1471-24072008-07-018120910.1186/1471-2407-8-209Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective studyViale GiuseppeValabrega GiorgioJacomuzzzi MariaDonadio MichelaNolè FrancoRedana StefaniaMontemurro FilippoSapino AnnaAglietta Massimo<p>Abstract</p> <p>Background</p> <p>The vinka-alkaloyd vinorelbine is a potentially valuable treatment in patients with HER2-positive, trastuzumab-resistant advanced breast cancer. We sought to document the clinical activity of vinorelbine-based salvage treatments in this clinical setting.</p> <p>Methods</p> <p>We analyzed a cohort of 424 consecutive women receiving trastuzumab-based therapy for HER2-positive advanced breast cancer. Of these, 299 were identified as progressing during the initial trastuzumab-based treatment, and 77 received vinorelbine-based therapy as first salvage treatment. Central review of pathological specimens revealed that 70 patients had HER2-amplification detected by FISH. For these patients we determined overall response rate (ORR = complete-CR + partial-PR) and clinical benefit (CB = CR+PR+ Stable disease lasting at least 6 months), time to progression (TTP) and overall survival (OS) from the initiation of vinorelbine-based salvage therapy.</p> <p>Results</p> <p>In 60 patients who were evaluable for tumor response, ORR and CB rates were 28% (95% C.I. 18%-41%) and 50% (95% C.I. 38%-62%), respectively. Median follow-up from the initiation of salvage therapy was 15 months (range 1–63 months). Median TTP and OS were 7.1 months (95% C.I. 6.6–7.7 months) and 21 months (95% C.I. 14.3–27.7 months), respectively. No differences in clinical outcomes were observed according to whether vinorelbine was administered as a single agent or in combination with other cytostatics, or whether trastuzumab was stopped or continued beyond disease progression.</p> <p>Conclusion</p> <p>our findings suggests that vinorelbine-based combinations are active and should be further evaluated in studies conducted in trastuzumab-resistant patients, including those evaluating newer HER2-targeting agents.</p>http://www.biomedcentral.com/1471-2407/8/209 |
| spellingShingle | Viale Giuseppe Valabrega Giorgio Jacomuzzzi Maria Donadio Michela Nolè Franco Redana Stefania Montemurro Filippo Sapino Anna Aglietta Massimo Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study BMC Cancer |
| title | Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study |
| title_full | Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study |
| title_fullStr | Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study |
| title_full_unstemmed | Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study |
| title_short | Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study |
| title_sort | vinorelbine based salvage therapy in her2 positive metastatic breast cancer patients progressing during trastuzumab containing regimens a retrospective study |
| url | http://www.biomedcentral.com/1471-2407/8/209 |
| work_keys_str_mv | AT vialegiuseppe vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT valabregagiorgio vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT jacomuzzzimaria vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT donadiomichela vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT nolefranco vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT redanastefania vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT montemurrofilippo vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT sapinoanna vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy AT agliettamassimo vinorelbinebasedsalvagetherapyinher2positivemetastaticbreastcancerpatientsprogressingduringtrastuzumabcontainingregimensaretrospectivestudy |